BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25073955)

  • 1. Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer.
    Ishikawa K; Nakamatsu K; Shiraishi O; Yasuda T; Nishimura Y
    Int J Clin Oncol; 2015 Jun; 20(3):531-7. PubMed ID: 25073955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.
    Lee JL; Park SI; Kim SB; Jung HY; Lee GH; Kim JH; Song HY; Cho KJ; Kim WK; Lee JS; Kim SH; Min YI
    Ann Oncol; 2004 Jun; 15(6):947-54. PubMed ID: 15151953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study.
    Hurmuzlu M; Øvrebø K; Monge OR; Smaaland R; Wentzel-Larsen T; Viste A
    World J Surg Oncol; 2010 Jun; 8():46. PubMed ID: 20515502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
    Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemoradiotherapy followed by surgery in treatment of locally advanced esophageal carcinoma: a phase II trial].
    Fu JH; Rong TH; Li XD; Hu Y; Ou W; Hu YH; Li Q
    Ai Zheng; 2004 Nov; 23(11 Suppl):1473-6. PubMed ID: 15566661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
    Wood MD; Zaki BI; Gordon SR; Sutton JE; Lisovsky M; Gui J; Bubis JA; Dragnev KH; Rigas JR
    J Thorac Oncol; 2013 Apr; 8(4):487-94. PubMed ID: 23370365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study.
    Hihara J; Hamai Y; Emi M; Murakami Y; Kenjo M; Nagata Y; Okada M
    Dis Esophagus; 2016 Nov; 29(8):1115-1120. PubMed ID: 26471962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
    Kleinberg L; Knisely JP; Heitmiller R; Zahurak M; Salem R; Burtness B; Heath EI; Forastiere AA
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):328-34. PubMed ID: 12738305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
    Chang KJ; Reid T; Senzer N; Swisher S; Pinto H; Hanna N; Chak A; Soetikno R
    Gastrointest Endosc; 2012 Jun; 75(6):1139-46.e2. PubMed ID: 22520270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
    Choong NW; Mauer AM; Haraf DC; Ferguson MK; Sandler AB; Kesler KA; Fishkin PA; Ansari RH; Wade J; Krauss SA; Sciortino DF; Posner MC; Kocherginsky M; Hoffman PC; Szeto L; Vokes EE
    Med Oncol; 2011 Dec; 28 Suppl 1():S152-61. PubMed ID: 20730572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.
    Caro M; Font A; Comas S; Viciano M; Remon J; Céliz P; Robles J; Musulén E; Sendrós MJ; Mesalles E; Jiménez JA; Boix J; Arellano A; Fernández-Llamazares J
    Clin Transl Oncol; 2016 Nov; 18(11):1106-1113. PubMed ID: 26856597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.